AngioSoma, Inc. (OTCMKTS:SOAN) Files An 8-K Regulation FD Disclosure
ITEM 7.01 Regulation FD Disclosure.
AngioSoma, Inc. (the “Company”) has entered into a partially binding letter of intent to acquire 50% of the equity interests in Diabetes Relief LLC. Diabetes Relief licenses medical facilities for the treatment of metabolic disorder, specializing in diabetes, for the use of patented protocols, processes, and intellectual property. Treatments are individualized to a patient’s condition and metabolic state. Diabetes Relief, through providing thousands of treatments, has seen vast improvements for patients. Clinical trials for FDA approval of LiprostinTM, that is intended to treat Peripheral Artery Disease, or PAD, may be facilitated by the acquisition.
Gross revenue of Diabetes Relief for the current year is forecasted to be $2,416,716. for the prior year $1,900,944, and for 2015 was $213,434. Revenue growth is expected to increase substantially.
ITEM 9.01 Financial Statements and Exhibits.
AngioSoma, Inc. Exhibit
EX-99 2 ex_99-1.htm LETTER OF INTENT – DIABETES RELIEF LLC Exhibit 99.1 December 1,…
To view the full exhibit click